Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exanta Superiority To Warfarin Could Reduce Safety Concerns – Cmte.

Executive Summary

AstraZeneca's Exanta should demonstrate more definitive superiority to Bristol-Myers Squibb's Coumadin (warfarin) prior to approval, FDA's Cardiovascular & Renal Drugs Advisory Committee agreed

You may also be interested in...



FDA's Pradaxa Quandary: Clearing Both Doses Could Mask Dabigatran's Superiority

The pivotal issue remaining for FDA's review of Boehringer Ingelheim's Pradaxa (dabigatran) is whether it will clear both the 110 mg and 150 mg doses and how it can craft labeling to guide appropriate use toward the higher dose, which seems likely to gain a superiority claim over warfarin.

AstraZeneca Rethinking Blockbuster Model After Exanta “Not Approvable”

FDA's "not approvable" decision for AstraZeneca's Exanta highlights the increasing difficulty of developing drugs with blockbuster potential while satisfying strict regulatory standards

AstraZeneca Rethinking Blockbuster Model After Exanta “Not Approvable”

FDA's "not approvable" decision for AstraZeneca's Exanta highlights the increasing difficulty of developing drugs with blockbuster potential while satisfying strict regulatory standards

Related Content

Topics

UsernamePublicRestriction

Register

PS142351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel